DAFTAR PUSTAKA

1. Djoerban Z, Djauzi. HIV/AIDS di Indonesia. Dalam: Buku Ajar Ilmu

Penyakit Dalam, Jilid III, Edisi V, Pusat Penerbit Departemen Ilmu
Penyakit Dalam FKUI, Jakarta: 2009 November; 2861-8.
2. Nasronudin. Penatalaksanaan Klinis Infeksi HIV & AIDS. Dalam : HIV
AIDS, Pendekatan Biologi Molekuler, Klinis dan Sosial. Barakbah J,
Soewandojo E, Suharto, Hardi U, Astuti WD. Universitas Airlangga.
Surabaya: 2007;31-43.
3. United National Programme on HIV/AIDS. Global report: UNAIDS report
on the global AIDS epidemic. 2012.
4. Kementrian Kesehatan Republik Indonesia. Pedoman Nasional
Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral pada Orang
Dewasa. Direktorat Jenderal Pengendalian Penyakit dan Penyehatas
Lingkungan. 2011.
5. Kementrian Kesehatan Republik Indonesia. Informasi Pengendalian
Penyakit Penyehatan Lingkungan. Direktorat Jenderal Pengendalian
Penyakit dan Penyehatan Lingkungan. 2013.
6. Dinkes Provinsi Sumatera Utara. Kasus HIV/AIDS. Bidang
Penanggulangan Penyakit Menular dan Penyehatan Lingkungan (P2MPL).
2013.
7. Fauci AS and Lane HC. Human Immunodeficiency Virus Disease : AIDS
and related disorder. In: Kasper DL, Fauci AS, Longo DL et al. Harrison’s
Principles of Internal Medicine Vol1.17th Edition. New York: Mc Graw
Hill Comparies. 2008;1076-96.
8. De Jesus E, Herrera G, Teofilo, Gerstoft J, Buendia CB, Brand JD, dkk.
Abacavir versus Zidovudine Combined with Lamivudine and Efavirenz,
for the Treatment of Antiretroviral-Naïve HIV-Infected Adult.
HIV/AIDS, Major Article, Clinical infection Disease. 2004 October 1
;39:1036-46.

Universitas Sumatera Utara

9. Sharma SK.Ziduvudine-induced anaemia in HIV/AIDS. Indian J Med Res
132. 2010 October;359-61.
10. Spaulding A, Rutherford GW, Siegfried N. Tenofovir or Zidovudine in
Three-Drug Combination Therapy with One Nucleoside Reverse
Transcriptase Inhibitor and One Non-Nucleoside Reverse Transcriptase
Inhibitor for Initial Treatment of HIV Infection in Antiretroviral-Naïve
individuals. Wiley.Cochrane Collaboration. 2011;2:1-28.
11. Montagnier L. 25 Years After HIV Discovery: Prospects for Cure and
Vaccine. Nobel Lucter, World Foundation for AIDS Research and
Prevention, UNESCO. 2008.
12. Belasio FE, Raimondo M, Suligoi B, Butto S. HIV Virology and
Pathogenetic Mechanisms of Infection: A Brief Overview, Ann 1st Super
Sanita. 2010;46(1):5-14.
13. Rey D, Hoen B, Chavent P et al. High Rate of Early Virological Failure
with The Once-Daily Tenofovir/Lamivudine/Nevirapine Combination in
Naïve HIV-1-Infected Patients. Journal of Antimicrobial Chemotherapy.
2009;63:380-3.
14. Wormster GP. The Epidemiology of HIV and AIDS in AIDS and other
Manifestation of HIV Infection. Medical Collage. New York. 2005.
15. Ammassari A, Antinori A, Cozzi-Lepri A et al. Relationship Between
HAART Adherence and Adipose Tissue Alterations, J Acquir Immune
Defic Syndr. 2002;31(Supple 3):140-4.
16. Jagriti P. Pharmacokinetic Boosting of Zidovudine for HIV Treatment, Int
J of Pharmac and Clin Research. 2012;4(3):31-6.
17. Max B, Sherer R. Management of the Adverse of Antiretroviral Therapy
and Medication Adherence. Clinical Infection Disease. 2000;30 (Suppl
2):S96-116.
18. Ghodke Y, Anderson P, Sangkuhl K. Pathway Zidovudine,
Farmacocinetic/Farmacodinamic. Pharmacogenomic. 2011; 5-10
19. Sperling R. Zidovudine. In: Infection Disease in Obstetric Gynecology.
1998;6:197-203.

Universitas Sumatera Utara

20. Castro AA, Acelio QR, Rey NA, Miguel EM, Farias PA. Determination
of the antiretroviral drug zidovudine in diluted alkaline electrolyte by
adsorptive stripping voltammetry at the mercury film electrode. American
Journal of Analytical Chemistry. 2011;2:223-34.
21. Manwar VJ, Sonawane VB, Patil VS, Takle SP. Rapid RP-HPLC method
for estimation of zidovudine from tablet dosage form, Der Chemica Sinica.
2011;2(5):152-6.
22. Duwal S, Schutte C, Kleist VM. Pharmacokinetics and pharmacodynamics
of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy
against HIV-1 infection, PLoS ONE. 2012;7:1-14
23. Velen K, Lewis JL, Charalambous S, Grant AD, Churchyard J, Hoffmann
CJ. Comparison of Tenofovir, Zidovudine, or Stavudine as Part of First-
Line Antiretroviral Therapy in a Resouce-Limited-Setting: A Cohort
Study. PloS One. 2013 May 14;8:1-8.
24. Agarwal D, Chakravarty J, Chaube L. High Incidence of Zidovudine
Induced Anemia in HIV Infected Patients in Eastern India. Indian J Med
Res. 2010;132:386-9.
25. Samal HB, Sreenivas SA, Dey S, Sharma H. Formulation and evaluation
of sustained release zidovudine matrix tablets. Int J Pharm Pharm sci.
2011;3(2):32-41.
26. Damian J, McColl, Michael D. The use of tenofovir disoproxil fumarate
for the treatment of nucleoside-resistent HIV-1. Journal of antimicrobial
chemotherapy. 2003;5:2013-223.
27. James MA, Ofotokun I, Sheth A, Acosta EP, King JR. Tenofovir: Once-
Daily Dosege in the Management of HIV Infection. Libertas Academic
Freedom to Research, Clinical Medicine Insight:Therapeutics. 2012;4:201-
16.
28. Bannon B. Retionale for tenofovir: As the first choice in the first-line
treatment of HIV, Medecins sains frontiers, Access Campaing. 2011;1-10.
29. Sturmer M, Staszewski S, Doerr HW. Quadruple nucleoside therapy with
zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Antiviral Therapy. 2007;12:695-703.

Universitas Sumatera Utara

30. Chakraborty H, Newman JE, Woelk G, Foday H, Peres JI. Antiretroviral
therapy initiation and CD4 progression over time among HIV infected
adults in centra Africa. Int J of Med and Public Health. 2011;1(4):3-11.
31. Esebelahie NO, Enweani IB, Omoregia R. Candida colonization in
asymptomatic HIV patients attending a tertiary hospital in Benin city,
Nigeria. Libyan J Med. 2013;8:20322.
32. Kothavade RJ, Kura MM, Valand AG, Panthaki MH. Candida tropicalis:
its prevalence, pathogenicity and increasing resistance to fluconazole. J
Med Micro. 2010;59:873-80.
33. Brun S, Berges T, Poupard P, Vauzelle C, Renier G, Chabasse, et al.
Mechanisms of azole resistance in petiti mutants of candida glabrata.
American society for microbiology. 2004;48(5):1788-96.
34. Gilks C. Application for inclusion of tenofovir disoproxil fumarate (TDF)
on WHO model list of essential medicine. Gilead Sciences. California,
USA. 2006;1-54.
35. Resino S, Bello MJ, Gurbindo et al. Viral Load and CD4+ Lymphocyte
Response to Hihgly Antiretroviral Therapy in Human Immunodeficiency
Virus Type-1-Infected Children: An Observational Study, HIV/AIDS.
Clinical Infection Disease. 2003:1216-25.

Universitas Sumatera Utara